SUPN קפיטליזציה חשבונאית Supernus

The market price visualization for Supernus Pharmaceuticals (SUPN) demonstrates the dynamics of an asset whose business relies on robotic screening and test automation in the development of neuropsychiatric drugs. The indicator stands at 1.03. Growth in the customer base is driven by the expansion of FDA approvals for children, although patent expirations create churn risks. Meanwhile, the company faces severe pressure from generics and industry behemoths in the epilepsy and ADHD segments.

This metric is calculated as the difference between all assets and liabilities, capturing the actual value of net resources available for development without resorting to external borrowing. For Supernus Pharmaceuticals (SUPN), such a base provides the financial cushion necessary for the market launch of the SPN-830 pump and the expansion of Qelbree, confirming business resilience through the company's balance sheet equity history.